 |
市場調查報告書
商品編碼
1304410
溶?體貯積病治療藥市場:各治療藥物，各適應症，各終端用戶，各地區- 市場規模，佔有率，展望，機會分析，2023年～2030年Lysosomal Storage Diseases Therapeutics Market, By Treatment (Enzyme Replacement Therapy ), By Indication, By End User, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
價格
簡介目錄
市場動態
溶?體貯積病的重要性日益增加、政府宣傳計劃的實施以及新產品的推出正在促進全球溶?體貯積病治療市場的增長。例如，2023年5月11日，美國製藥公司Chiesi USA, Inc.宣布其產品Elfabrio獲得美國食品藥品監督管理局批准。它在?替代療法（ERT）中使用pegunigalsidase alfa來治療確診的法布里病成年患者。
本調查的主要特徵
- 本報告提供以2021年為基準年的預測期間（2022-2030 年）之全球溶?體貯積病治療藥市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
- 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
- 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
- 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球溶?體貯積病治療藥市場的主要參與者之企業簡介。
- 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
- 全球牛血清市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
- 利益相關者可以透過全球溶?體貯積病治療藥市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。
目錄
第1章 調查目的與前提條件
- 調查目的
- 前提條件
- 簡稱
第2章 市場概況
- 報告概要
- 市場定義和範圍
- 摘要整理
- 連貫·機遇·地圖(COM)
第3章 市場動態，法規，趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機會
- 影響分析
- 最近的產品上市
- 流行病學
- 合併，收購，聯盟
- 法規情勢
- 主要的發展
- PEST分析
第4章 溶?體貯積病治療藥的全球市場:COVID-19影響分析
- 經濟影響
- COVID-19流行病學
- 供需的影響
第5章 溶?體貯積病治療藥的全球市場:各治療藥物，2018年～2030年
- 酵素補充療法
- 幹細胞療法
- 基材降低療法
- 其他
第6章 溶?體貯積病治療藥的全球市場:各適應症，2018年～2030年
- 高雪氏症
- 法布瑞氏症
- 龐貝氏症
- 黏多醣症
- 其他
第7章 溶?體貯積病治療藥的全球市場:各終端用戶，2018年～2030年
- 醫院
- 診療所
第8章 溶?體貯積病治療藥的全球市場:各地區，2018-2030年
- 北美
- 美國
- 加拿大
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他南美國家
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 中東
- GCC
- 以色列
- 其他中東
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情形
- Shire plc
- Pfizer, Inc.
- Sanofi SA
- BioMarin Pharmaceutical Inc
- Actelion Ltd.
- Raptor Pharmaceutical Corp
- Protalix Biotherapeutics Inc.
- Amicus Therapeutics, Inc.
第10章 章節
- 調查手法
- 關於出版社
簡介目錄
Product Code: CMI3651
Lysosomal storage diseases (LSDs) are diseases caused by defects in single-genes. Enzyme defects cause nearly seventy percent of the LSDs, and the rest are defects in enzyme activator or associated proteins. A gene on a particular chromosome locus transcribes a particular enzyme, improper enzyme-coding results in inactive enzymes. Similarly, defective activators result from mutations in activator genes. These conditions cause disease of the organs in which they accumulate and decide the clinical signs and symptoms. Infants and children suffer more severely compared to adults. The clinical features are unique in many children and adults for the same disease. For example, the child's developing brain is more susceptible to insults and manifests symptoms and signs of dysfunction, while this may be milder or absent in adults. Enzyme testing is usually the initial diagnostic test, but genetic analysis of the gene mutations adds precision. There are many modern therapeutic techniques for these conditions. When applied early before organ damage sets in, these therapies have the potential to prevent or delay damage, improve quality of life, and increase lifespan.
Market Dynamics
Increasing significance of lysosomal storage diseases, arrangement of awareness programs by governments and the launch of new products are attributed to the growth of the global lysosomal storage diseases therapeutics market. For instance, on May 11, 2023, Chiesi USA, Inc., a U.S. based pharmaceutical company announced that its product Elfabrio was approved by U.S. Food and Drug Administration. It uses the enzyme pegunigalsidase alfa for enzyme replacement therapy (ERT) to treat adults with confirmed Fabry disease.
Key features of the study:
- This report provides an in-depth analysis of the global lysosomal storage diseases therapeutics market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revaenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global lysosomal storage diseases therapeutics market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Shire plc, Pfizer, Inc., Sanofi, BioMarin Pharmaceutical Inc., Actelion Ltd., Raptor Pharmaceutical Corp., Protalix Biotherapeutics Inc., Quest Diagnostics, and Amicus Therapeutics, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global lysosomal storage diseases therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lysosomal storage diseases therapeutics market.
Detailed Segmentation:
- Global Lysosomal Storage Diseases Therapeutics Market, By Treatment:
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Substrate Reduction Therapy
- Others
- Global Lysosomal Storage Diseases Therapeutics Market, By Indication:
- Gaucher's Disease
- Fabry Disease
- Pompe's Syndrome
- Mucopolysaccharidosis
- Others
- Global Lysosomal Storage Diseases Therapeutics Market, By End User:
- Hospitals
- Clinics
- Global Lysosomal Storage Diseases Therapeutics Market, By Geography:
- North America
- By Country:
- U.S.
- Canada
- Europe
- By Country:
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Country:
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East:
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region:
- Central Africa
- South Africa
- North Africa
- North America
- Company Profiles
- Shire plc*
- Company Overview
- Product Portfolio
- Financial Performance
- Key Strategies
- Recent Developments
- Pfizer, Inc.
- Sanofi SA
- BioMarin Pharmaceutical Inc
- Actelion Ltd.
- Raptor Pharmaceutical Corp.
- Protalix Biotherapeutics Inc.
- Amicus Therapeutics, Inc.
- Shire plc*
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Treatment
- Market Snapshot, By Indication
- Market Snapshot, By End user
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Lysosomal Storage Diseases Therapeutics Market- COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Lysosomal Storage Diseases Therapeutics Market, By Treatment, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 -2030
- Segment Trends
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Substrate Reduction Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
6. Global Lysosomal Storage Diseases Therapeutics Market, By Indication, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 -2030
- Segment Trends
- Gaucher's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Fabry Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Pompe's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Mucopolysaccharidosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
7. Global Lysosomal Storage Diseases Therapeutics Market, By End user, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 -2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
8. Global Lysosomal Storage Diseases Therapeutics Market, By Region, 2018-2030, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2018 -2030
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018 - 2030, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication , 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2018 - 2030, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2018- 2030, (US$ Billion)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Shire plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer, Inc.
- Sanofi SA
- BioMarin Pharmaceutical Inc
- Actelion Ltd.
- Raptor Pharmaceutical Corp
- Protalix Biotherapeutics Inc.
- Amicus Therapeutics, Inc.
10. Section
- Research Methodology
- About Us
